Study details
Enrolling now
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics LLC
NCT IDNCT05645107ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
386
Study length
about 3.5 years
Ages
18+
Locations
7 sites in CA, FL, MD +3
About this study
This trial is testing whether biweekly XEMBIFY® plus Standard Medical Treatment (SMT) will reduce the rate of major bacterial infections in people with B-cell CLL, MM, or NHL who have low antibody levels. Participants will receive either XEMBIFY® and SMT or a placebo and SMT for one year.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Xembify
PhasePhase 3
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Oncology